| abstract |
The present invention provides new indole, indazole, benzimidazole, indoline, quinolone, isoquinoline and carbazole selective androgen receptor degradation (SARD) compound, its pharmaceutical composition and in the treatment of prostate cancer, advanced prostate cancer, castration-resistant prostate cancer, androgenetic alopecia or other hyperandrogenic skin diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS) and uterine fibroids, and to reduce Levels of disease-mutant and/or resistance-mutant androgen receptor‑full-length (AR‑FL), AR‑splice variant (AR‑SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR Methods. |